What Researchers Did
Researchers retrospectively evaluated the efficacy and tolerability of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy in 44 patients with stage IV non-small cell lung cancer.
What They Found
The overall response rate was 61.4%, with 15.9% of patients achieving stable disease. The mean overall survival was 42.9 months (95% CI: 34.0-51.8), and mean progression-free survival was 41.0 months (95% CI: 31.1-50.9). The combination therapy was well-tolerated, with acceptable toxicity and no significant problems related to the adjunctive therapies.
What This Means for Canadian Patients
This study suggests a potential new approach for treating advanced non-small cell lung cancer that combines chemotherapy with metabolic support and other modalities. If further research confirms these findings, it could offer Canadian patients with metastatic NSCLC a novel treatment option with promising survival outcomes and good tolerability.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or patients.
Study Limitations
A key limitation of this study is its retrospective design, which can be prone to selection bias and confounding factors.